The ABCs of BMPs.
Bone morphogenetic proteins (BMP) are being increasingly used in orthopaedic surgery. These small molecules are capable of inducing bone formation when delivered in the appropriate concentration and on the appropriate scaffold. Not all BMPs are equally effective, and there are currently only two Food and Drug Administration (FDA)-approved "on-label" applications. There are potential complications related to off-label use of BMPs that need to be understood. When used properly, these molecules have the potential to eliminate the need for iliac crest bone graft harvest and improve the speed and success of bone healing.
Boden
Scott D
SD
Emory Orthopaedics & Spine Center, Emory University School of Medicine, Atlanta, GA, USA.
D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000009:adverse effects / Q000502:physiology / Q000627:therapeutic use; D001861:Bone Regeneration / Q000187:drug effects / Q000502:physiology; D017277:Drug Approval; D004348:Drug Labeling; D017102:Fracture Healing / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007085:Ilium / Q000637:transplantation; D016348:Osseointegration / Q000187:drug effects / Q000502:physiology; D012307:Risk Factors; D013123:Spinal Fusion; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D016212:Transforming Growth Factor beta